Greece

Greece

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.8 (1.65 - 1.97) 2019 Modelled IHME
1.8 (1.65 - 1.96) 2018 Modelled IHME
1.81 (1.63 - 1.97) 2017 Modelled IHME
1.81 (1.64 - 1.97) 2016 Modelled IHME
1.81 (1.64 - 2) 2015 Modelled IHME
1.82 (1.65 - 2) 2014 Modelled IHME
1.83 (1.67 - 2.01) 2013 Modelled IHME
1.84 (1.68 - 2.02) 2012 Modelled IHME
1.86 (1.69 - 2.04) 2011 Modelled IHME
1.87 (1.71 - 2.06) 2010 Modelled IHME
1.89 (1.73 - 2.07) 2009 Modelled IHME
1.91 (1.75 - 2.09) 2008 Modelled IHME
1.93 (1.77 - 2.10) 2007 Modelled IHME
1.95 (1.77 - 2.13) 2006 Modelled IHME
1.97 (1.78 - 2.16) 2005 Modelled IHME
1.99 (1.81 - 2.18) 2004 Modelled IHME
2.01 (1.83 - 2.20) 2003 Modelled IHME
2.03 (1.85 - 2.21) 2002 Modelled IHME
2.04 (1.87 - 2.24) 2001 Modelled IHME
2.06 (1.88 - 2.27) 2000 Modelled IHME
2.08 (1.90 - 2.28) 1999 Modelled IHME
2.1 (1.92 - 2.30) 1998 Modelled IHME
2.12 (1.94 - 2.33) 1997 Modelled IHME
2.14 (1.95 - 2.35) 1996 Modelled IHME
2.15 (1.95 - 2.37) 1995 Modelled IHME
2.17 (1.97 - 2.38) 1994 Modelled IHME
2.18 (1.98 - 2.40) 1993 Modelled IHME
2.2 (2 - 2.42) 1992 Modelled IHME
2.21 (2.01 - 2.44) 1991 Modelled IHME
2.22 (2.01 - 2.47) 1990 Modelled IHME
3.3 (2.20 - 4.70) 2010 Modelled Drositis I et al, 2013
1.14 (0.91 - 1.46) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.05 (0.04 - 0.07) 2019 Modelled IHME
0.05 (0.04 - 0.07) 2018 Modelled IHME
0.05 (0.04 - 0.07) 2017 Modelled IHME
0.05 (0.04 - 0.07) 2016 Modelled IHME
0.05 (0.04 - 0.07) 2015 Modelled IHME
0.05 (0.04 - 0.07) 2014 Modelled IHME
0.05 (0.04 - 0.07) 2013 Modelled IHME
0.06 (0.04 - 0.07) 2012 Modelled IHME
0.06 (0.04 - 0.07) 2011 Modelled IHME
0.06 (0.04 - 0.08) 2010 Modelled IHME
0.06 (0.04 - 0.08) 2009 Modelled IHME
0.06 (0.05 - 0.08) 2008 Modelled IHME
0.07 (0.05 - 0.09) 2007 Modelled IHME
0.07 (0.05 - 0.09) 2006 Modelled IHME
0.07 (0.05 - 0.10) 2005 Modelled IHME
0.08 (0.06 - 0.10) 2004 Modelled IHME
0.08 (0.06 - 0.11) 2003 Modelled IHME
0.09 (0.07 - 0.12) 2002 Modelled IHME
0.1 (0.07 - 0.13) 2001 Modelled IHME
0.11 (0.09 - 0.14) 2000 Modelled IHME
0.18 (0.14 - 0.23) 1999 Modelled IHME
0.32 (0.25 - 0.42) 1998 Modelled IHME
0.49 (0.38 - 0.64) 1997 Modelled IHME
0.63 (0.49 - 0.82) 1996 Modelled IHME
0.71 (0.54 - 0.94) 1995 Modelled IHME
0.73 (0.55 - 0.96) 1994 Modelled IHME
0.75 (0.56 - 1) 1993 Modelled IHME
0.77 (0.57 - 1.02) 1992 Modelled IHME
0.78 (0.57 - 1.04) 1991 Modelled IHME
0.78 (0.57 - 1.05) 1990 Modelled IHME
0.37 (0.25 - 0.52) 2015 Modelled WHO
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
2.9 (2.40 - 3.50) 2003 Survey/reported Papaevangelou V et al, 2006

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
32 (24 - 42) 2019 Modelled IHME
32 (24 - 42) 2018 Modelled IHME
32 (24 - 42) 2017 Modelled IHME
32 (24 - 42) 2016 Modelled IHME
32 (24 - 42) 2015 Modelled IHME
32 (24 - 42) 2014 Modelled IHME
32 (24 - 43) 2013 Modelled IHME
32 (24 - 42) 2012 Modelled IHME
32 (24 - 42) 2011 Modelled IHME
32 (24 - 42) 2010 Modelled IHME
32 (24 - 42) 2009 Modelled IHME
32 (24 - 42) 2008 Modelled IHME
33 (24 - 43) 2007 Modelled IHME
34 (25 - 44) 2006 Modelled IHME
34 (25 - 44) 2005 Modelled IHME
34 (25 - 44) 2004 Modelled IHME
34 (25 - 44) 2003 Modelled IHME
34 (25 - 44) 2002 Modelled IHME
34 (25 - 44) 2001 Modelled IHME
34 (25 - 44) 2000 Modelled IHME
34 (25 - 44) 1999 Modelled IHME
34 (25 - 44) 1998 Modelled IHME
34 (25 - 44) 1997 Modelled IHME
34 (25 - 44) 1996 Modelled IHME
34 (25 - 44) 1995 Modelled IHME
34 (25 - 44) 1994 Modelled IHME
34 (25 - 43) 1993 Modelled IHME
34 (25 - 43) 1992 Modelled IHME
34 (25 - 43) 1991 Modelled IHME
34 (25 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
95 2008 Survey/reported WHO/UNICEF
95 2007 Survey/reported WHO/UNICEF
94 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
92 2003 Survey/reported WHO/UNICEF
91 2002 Survey/reported WHO/UNICEF
90 2001 Survey/reported WHO/UNICEF
89 2000 Survey/reported WHO/UNICEF
88 1999 Survey/reported WHO/UNICEF
69 1998 Survey/reported WHO/UNICEF
50 1997 Survey/reported WHO/UNICEF
12 1996 Survey/reported WHO/UNICEF
12 1995 Survey/reported WHO/UNICEF
2 1994 Survey/reported WHO/UNICEF
2 1993 Survey/reported WHO/UNICEF
15 1992 Survey/reported WHO/UNICEF
10 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
76 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
NSP in at least one prison
No
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.61 (0.50 - 0.75) 2019 Modelled IHME
0.61 (0.50 - 0.74) 2018 Modelled IHME
0.6 (0.49 - 0.74) 2017 Modelled IHME
0.59 (0.49 - 0.73) 2016 Modelled IHME
0.58 (0.47 - 0.72) 2015 Modelled IHME
0.57 (0.47 - 0.71) 2014 Modelled IHME
0.57 (0.47 - 0.70) 2013 Modelled IHME
0.56 (0.46 - 0.69) 2012 Modelled IHME
0.56 (0.46 - 0.69) 2011 Modelled IHME
0.56 (0.46 - 0.68) 2010 Modelled IHME
0.55 (0.45 - 0.68) 2009 Modelled IHME
0.55 (0.45 - 0.68) 2008 Modelled IHME
0.55 (0.45 - 0.68) 2007 Modelled IHME
0.54 (0.44 - 0.68) 2006 Modelled IHME
0.54 (0.44 - 0.67) 2005 Modelled IHME
0.52 (0.43 - 0.64) 2004 Modelled IHME
0.48 (0.40 - 0.59) 2003 Modelled IHME
0.44 (0.36 - 0.54) 2002 Modelled IHME
0.41 (0.34 - 0.49) 2001 Modelled IHME
0.39 (0.32 - 0.48) 2000 Modelled IHME
0.39 (0.32 - 0.47) 1999 Modelled IHME
0.4 (0.33 - 0.47) 1998 Modelled IHME
0.4 (0.33 - 0.48) 1997 Modelled IHME
0.4 (0.33 - 0.48) 1996 Modelled IHME
0.41 (0.34 - 0.49) 1995 Modelled IHME
0.42 (0.35 - 0.50) 1994 Modelled IHME
0.45 (0.37 - 0.54) 1993 Modelled IHME
0.48 (0.40 - 0.58) 1992 Modelled IHME
0.53 (0.44 - 0.64) 1991 Modelled IHME
0.58 (0.47 - 0.71) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2.2 (1.30 - 3.40) 2010 Survey/reported Drositis et al, 2013
1.9 (0.50 - 2.60) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
65.7 (61.80 - 69.50) 2014 Modelled Degenhardt L et al, 2017
68.1 (65.50 - 70.60) 2013 Survey/reported EMCDDA
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (15 - 28) 2019 Modelled IHME
21 (15 - 28) 2018 Modelled IHME
21 (15 - 28) 2017 Modelled IHME
21 (14 - 28) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 27) 2009 Modelled IHME
20 (14 - 27) 2008 Modelled IHME
20 (14 - 26) 2007 Modelled IHME
19 (14 - 26) 2006 Modelled IHME
19 (13 - 26) 2005 Modelled IHME
19 (14 - 25) 2004 Modelled IHME
19 (14 - 25) 2003 Modelled IHME
19 (13 - 25) 2002 Modelled IHME
19 (13 - 25) 2001 Modelled IHME
19 (13 - 25) 2000 Modelled IHME
19 (13 - 25) 1999 Modelled IHME
19 (14 - 25) 1998 Modelled IHME
19 (14 - 26) 1997 Modelled IHME
19 (14 - 26) 1996 Modelled IHME
19 (14 - 26) 1995 Modelled IHME
19 (14 - 26) 1994 Modelled IHME
19 (14 - 26) 1993 Modelled IHME
19 (14 - 26) 1992 Modelled IHME
20 (14 - 26) 1991 Modelled IHME
20 (14 - 27) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
53 (43 - 65) 2014 Survey/reported Reitox National Focal Point, 2014
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
65 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
NSP in at least one prison
No
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.8 (%)
2019
(1.65 - 1.97(%))
IHME
HCV (RNA/cAg+)
0.61 (%)
2019
(0.5 - 0.75(%))
IHME

Survey/surveillance

No data available
HCV (anti-HCV)
2.2 (%)
2010
(1.3 - 3.4(%))
Drositis et al, 2013

Hepatitis related deaths (national)

Modelled

HBV
372
2019
(299 - 463)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
397
2019
(306 - 502)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.05 (%)
2019, latest modelled
(0.04 - 0.07(%))
IHME

Prevalence PWID

HCV
68.10 (%)
2013, survey/surveillance
(65.50 - 70.60(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
76
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines